Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 5/20 | 0.60 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | NEK2 | P51955 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779070 | 0.82 | POLA1 (0.40) | POLA1NPC1TP53TSHRHTT | |
| SCHEMBL18231630 | 0.77 | POLA1 (0.64) | POLA1 | |
| SCHEMBL7666283 | 0.74 | POLA1 (0.60) | POLA1CDK2NEK2SYK | |
| SCHEMBL8539783 | 0.74 | CDK2 (0.64) | POLA1CDK2NEK2PDPK1JAK2 | |
| SCHEMBL5197101 | 0.66 | GDA (0.54) | POLA1NEK2BRAFDPP4 | |
| SCHEMBL7293081 | 0.66 | DPP4 (0.56) | POLA1CDK2PDPK1DPP4 | |
| SCHEMBL27824249 | 0.66 | DPP4 (0.61) | POLA1CDK2BRAFPDPK1DPP4 | |
| SCHEMBL9278629 | 0.66 | POLA1 (0.59) | POLA1CDK2HTTDPP4 | |
| SCHEMBL4307867 | 0.66 | DPP4 (0.49) | POLA1NEK2HSD17B10DPP4 | |
| SCHEMBL6551675 | 0.66 | DPP4 (0.56) | POLA1NEK2PDPK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472254-A4 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | GLSYNTHESIS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-6926763-B2 | Purine and isosteric antibacterial compounds | GLSYNTHESIS, INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1472254-A2 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | Glsynthesis Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040014773-A1 | Purine and isosteric antibacterial compounds | ACURX PHARMACEUTICALS, LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2003066586-A2 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | GLSYNTHESIS INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014773-A1 | Purine and isosteric antibacterial compounds | MTAP, AMPD3, MPG | POLA1 75/4885CDK2 908/4885NEK2 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.